相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The next tier of EGFR resistance mutations in lung cancer
Hannah L. Tumbrink et al.
ONCOGENE (2021)
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
Shuo Chen et al.
CANCER CELL (2021)
Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity
Viralkumar Davra et al.
CANCER RESEARCH (2021)
Multi-organ proteomic landscape of COVID-19 autopsies
Xiu Nie et al.
CELL (2021)
Phosphorylation of PKCδ by FER tips the balance from EGFR degradation to recycling
Ana Lonic et al.
JOURNAL OF CELL BIOLOGY (2021)
Selective exosome exclusion of miR-375 by glioma cells promotes glioma progression by activating the CTGF-EGFR pathway
Xiangdong Xu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target
Xiuning Le et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT-MET switch and cancer metastasis
Wei-Hsin Lin et al.
ONCOGENE (2021)
Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB
Manikandan Periyasamy et al.
ONCOGENE (2021)
Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine
Cristina P. R. Xavier et al.
CANCER LETTERS (2021)
Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition
Yael Cohen-Sharir et al.
NATURE (2021)
Whole-genome doubling confers unique genetic vulnerabilities on tumour cells
Ryan J. Quinton et al.
NATURE (2021)
Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer
Shiqi Ma et al.
ONCOGENE (2021)
Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors
Yue Liu et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway
Wenwen Du et al.
CELL DEATH AND DIFFERENTIATION (2021)
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
Vanita Noronha et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
Yukio Hosomi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
Kari J. Kurppa et al.
CANCER CELL (2020)
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
Adam J Schoenfeld et al.
CLINICAL CANCER RESEARCH (2020)
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis
Hong Liu et al.
CANCER CELL (2020)
A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors
Ina Nemet et al.
CELL (2020)
MAML1/2 promote YAP/TAZ nuclear localization and tumorigenesis
Jiyoung Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Cross-talk between SOX2 and TGF beta Signaling Regulates EGFR-TKI Tolerance and Lung Cancer Dissemination
Ming-Han Kuo et al.
CANCER RESEARCH (2020)
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment
Jianchun Duan et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
Monique B. Nilsson et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Interaction of non-coding RNAs and Hippo signaling: Implications for tumorigenesis
Can Liu et al.
CANCER LETTERS (2020)
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
Youjin Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
Michael Offin et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
Jordi Bertran-Alamillo et al.
NATURE COMMUNICATIONS (2019)
Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening
Gabriele Picco et al.
NATURE COMMUNICATIONS (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer
Caiyun Wang et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma
Jacopo Gavini et al.
CELL DEATH & DISEASE (2019)
The Hippo Pathway: Biology and Pathophysiology
Shenghong Ma et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 88 (2019)
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
Khyati N. Shah et al.
NATURE MEDICINE (2019)
NTRK1 is a positive regulator of YAP oncogenic function
Xinyuan Yang et al.
ONCOGENE (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer
Bernhard W. Renz et al.
CANCER CELL (2018)
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2018)
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
Chiara Tomasello et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer
Amritha Nair et al.
NATURE MEDICINE (2018)
Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells
Debangshu Samanta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
Zhijie Wang et al.
LANCET RESPIRATORY MEDICINE (2018)
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis
Niki Karachaliou et al.
EBIOMEDICINE (2018)
Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4
Francesca Zanconato et al.
NATURE MEDICINE (2018)
Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer
Pei-Chih Lee et al.
CANCER CELL (2018)
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
Imane Chaib et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Collin M. Blakely et al.
NATURE GENETICS (2017)
Hippo pathway mediates resistance to cytotoxic drugs
Taranjit S. Gujral et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers
Monique B. Nilsson et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Kirstine Jacobsen et al.
NATURE COMMUNICATIONS (2017)
Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)
Carles Codony-Servat et al.
ONCOTARGET (2017)
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
Imane Chaib et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts
Jung Ho Kim et al.
CANCER SCIENCE (2017)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
Eiki Ichihara et al.
CANCER RESEARCH (2017)
Hippo Signaling Suppresses Cell Ploidy and Tumorigenesis through Skp2
Shihao Zhang et al.
CANCER CELL (2017)
m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program
Sicong Zhang et al.
CANCER CELL (2017)
PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation
De-Wei Wu et al.
CLINICAL CANCER RESEARCH (2016)
Inhibition of FoxM1-Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis
Subapriya Rajamanickam et al.
CLINICAL CANCER RESEARCH (2016)
HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer
Gaofeng Fan et al.
GENES & DEVELOPMENT (2016)
Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Xiaoxiao Sun et al.
MOLECULAR CANCER THERAPEUTICS (2016)
HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes
J. Cui et al.
ONCOGENE (2016)
TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells
Sandra Pinet et al.
ONCOTARGET (2016)
AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
Moshe Elkabets et al.
CANCER CELL (2015)
A gp130-Src-YAP module links inflammation to epithelial regeneration
Koji Taniguchi et al.
NATURE (2015)
The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking
Leila Belle et al.
SCIENCE SIGNALING (2015)
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
Erin M. Tricker et al.
CANCER DISCOVERY (2015)
The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking
Leila Belle et al.
SCIENCE SIGNALING (2015)
Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer
Takeshi Yoshida et al.
CLINICAL CANCER RESEARCH (2014)
Genetic modifiers of EGFR dependence in non-small cell lung cancer
Tanaz Sharifnia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2013)
Mediating Resistance in Oncogene-Driven Cancers
Rafael Rosell
NEW ENGLAND JOURNAL OF MEDICINE (2013)
HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors
S. Gusenbauer et al.
ONCOGENE (2013)
Connective tissue growth factor is a new ligand of epidermal growth factor receptor
Sandra Rayego-Mateos et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2013)
Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition
Matias Casas-Selves et al.
CANCER RESEARCH (2012)
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Sidong Huang et al.
CELL (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker
Dahu Chen et al.
NATURE MEDICINE (2012)
A Tight Junction-Associated Merlin-Angiomotin Complex Mediates Merlin's Regulation of Mitogenic Signaling and Tumor Suppressive Functions
Chunling Yi et al.
CANCER CELL (2011)
MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents
Weiwen Fan et al.
CANCER RESEARCH (2011)
Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase
Tingting Sun et al.
CELL (2011)
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Trever G. Bivona et al.
NATURE (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
Martin L. Sos et al.
CANCER RESEARCH (2009)
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
Sizhi Paul Gao et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Jayne M. Stommel et al.
SCIENCE (2007)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)